Status:
COMPLETED
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Pfizer
Conditions:
Venous Thrombosis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatm...
Eligibility Criteria
Inclusion
- Men and women ≥ 18 years of age;
- Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);
- Anticoagulant treatment completed
- No recurrence of Venous Thromboembolism (VTE)
Exclusion
- Subjects with indications for long-term treatment with a vitamin K antagonist
- Active bleeding or high risk for serious bleeding
- Short life expectancy
- Uncontrolled high blood pressure
- Impaired kidney or liver function
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
2711 Patients enrolled
Trial Details
Trial ID
NCT00633893
Start Date
May 1 2008
End Date
August 1 2012
Last Update
November 25 2013
Active Locations (428)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Clinical Therapeutics, Llc
Birmingham, Alabama, United States, 35235
2
Cardiovascular Consultants, Ltd.
Phoenix, Arizona, United States, 85032
3
Robert J. Bloomberg, Md, Pc
Tempe, Arizona, United States, 85283
4
Fort Smith Lung Center
Fort Smith, Arkansas, United States, 72901